Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Giesel, Frederik L. [VerfasserIn]   i
 Knorr, Karina [VerfasserIn]   i
 Spohn, Fabian [VerfasserIn]   i
 Will, Leon [VerfasserIn]   i
 Maurer, Tobias [VerfasserIn]   i
 Flechsig, Paul [VerfasserIn]   i
 Schiller, Christoph Kilian [VerfasserIn]   i
 Weber, Wolfgang Andreas [VerfasserIn]   i
 Haberkorn, Uwe [VerfasserIn]   i
 Schwaiger, Markus [VerfasserIn]   i
 Kratochwil, Clemens [VerfasserIn]   i
 Kramer, Vasko [VerfasserIn]   i
 Kopka, Klaus [VerfasserIn]   i
 Eiber, Matthias [VerfasserIn]   i
Titel:Detection efficacy of F-18-PSMA-1007 PET/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy
Verf.angabe:Frederik L. Giesel, Karina Knorr, Fabian Spohn, Leon Will, Tobias Maurer, Paul Flechsig, Oliver Neels, Kilian Schiller, Horacio Amaral, Wolfgang A. Weber, Uwe Haberkorn, Markus Schwaiger, Clemens Kratochwil, Peter Choyke, Vasko Kramer, Klaus Kopka, and Matthias Eiber
Jahr:2019
Umfang:7 S.
Fussnoten:First published July 24, 2018 ; Gesehen am 04.04.2019 ; Im Titel ist „18“ hochgestellt
Titel Quelle:Enthalten in: Journal of nuclear medicine
Ort Quelle:New York, NY : Soc., 1964
Jahr Quelle:2019
Band/Heft Quelle:60(2019), 3, Seite 362-368
ISSN Quelle:2159-662X
 1535-5667
Abstract:Prostate-specific membrane antigen (PSMA)-targeted PET imaging recently emerged as a new method for the staging and restaging of prostate cancer. Most published studies investigated the diagnostic potential of Ga-68-labeled PSMA agents that are excreted renally. F-18-PSMA-1007 is a novel PSMA ligand that has excellent preclinical characteristics and that is only minimally excreted by the urinary tract, a potential advantage for pelvic imaging. The aim of this study was to investigate the diagnostic efficacy of F-18-PSMA-1007 for biochemical recurrence (BCR) after radical prostatectomy. Methods: From 3 academic centers, 251 patients with BCR after radical prostatectomy were evaluated in a retrospective analysis. Patients who had received second-line androgen deprivation therapy (ADT) or chemotherapy were excluded, but prior first-line ADT exposure was allowed. The median prostate-specific antigen (PSA) level was 1.2 ng/mL (range, 0.2-228 ng/mL). All patients underwent PSMA PET/CT at 92 +/- 26 min after injection of 301 +/- 46 MBq of F-18-PSMA-1007. The rate of detection of presumed recurrence sites was correlated with the PSA level and original primary Gleason score. A comparison to a subset of patients treated previously with ADT was undertaken. Results: Of the 251 patients, 204 (81.3%) had evidence of recurrence on F-18-PSMA-1007 PET/CT. The detection rates were 94.0% (79/84), 90.9% (50/55), 74.5% (35/47), and 61.5% (40/65) for PSA levels of greater than or equal to 2, 1 to less than 2, 0.5 to less than 1, and 0.2 to less than 0.5 ng/mL, respectively. F-18-PSMA-1007 PET/CT revealed local recurrence in 24.7% of patients (n = 62). Lymph node metastases were present in the pelvis in 40.6% of patients (n = 102), in the retroperitoneum in 19.5% of patients (n = 49), and in supradiaphragmatic locations in 12.0% of patients (n = 30). Bone and visceral metastases were detected in 40.2% of patients (n = 101) and in 3.6% of patients (n = 9), respectively. In tumors with higher Gleason scores (<= 7 vs. >= 8), detection efficacy trended higher (76.3% vs. 86.7%) but was not statistically significant (P = 0.32). However, detection efficacy was higher in patients who had received ADT (91.7% vs. 78.0%) within 6 mo before imaging (P = 0.0179). Conclusion: F-18-PSMA-1007 PET/CT offers high detection rates for BCR after radical prostatectomy that are comparable to or better than those published for Ga-68-labeled PSMA ligands.
DOI:doi:10.2967/jnumed.118.212233
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.2967/jnumed.118.212233
 DOI: https://doi.org/10.2967/jnumed.118.212233
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:biodistribution
 pet/ct
 radiation-dosimetry
 biochemical recurrence
 diagnosis
 disease
 f-18-psma-1007
 ga-68-labeled psma ligand
 ga-68-psma pet/ct
 hybrid imaging
 local recurrence
 membrane antigen
 pet/mri
 prostate cancer
 rising psa
K10plus-PPN:1662849796
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68378595   QR-Code
zum Seitenanfang